Cefazolin
Paul G. Auwaerter, M.D.
,
Edina Avdic, Pharm.D.
Pediatric Dosing Author:
Alice Jenh Hsu, PharmD, BCPS, AQ-ID
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
FDA
Respiratory tract infections
Due to
S. pneumoniae
,
S. aureus
(MSSA) and
S. pyogenes
Urinary tract infections
Due to
E. coli
,
P. mirabilis
Prostatitis
and
epididymitis
Due to
E. coli
, P
P. mirabilis
Skin and skin structure infections
Due to
S. aureus
(MSSA),
S. pyogenes
, and other strains of streptococci
Biliary tract infections
Due to
E. coli
, various strains of streptococci,
P. mirabilis
, and
S. aureus
(MSSA)
Bone and joint infections due to
S. aureus
(MSSA)
Septicemia
Due to
S. pneumoniae
,
S. aureus
(MSSA),
P. mirabilis
,
E. coli
Endocarditis
Due to
S. aureus
(MSSA) and
S. pyogenes
Perioperative prophylaxis
NON-FDA APPROVED USES
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Parotitis
(MSSA)
Other
Staphylococcus aureus
(MSSA) infections
Other
Streptococcus pyogenes
(Group A) infections
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2023 Unbound Medicine, Inc. All rights reserved